Filing Flows › Health Care › Prelude Therapeutics (PRLD)
Prelude Therapeutics (PRLD) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 11, 2026 · Prelude Therapeutics (PRLD) Q2 2026 earnings results →
Q2 2026 244¢ of every $1 of revenue lost · operating margin -270.9%
Prelude Therapeutics made $5.7M in Q2 2026. Operating margin -270.9%, net loss $13.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $5.7M in Q2 2026, up 25% from the previous quarter.
Operating costs exceeded revenue by $15.5M, an operating margin of -270.9%. The quarter ended with a net loss of $13.9M, wider than the previous quarter's $10.4M loss.
Operating cash flow was −$15.6M. Non-cash charges added back $353K of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $4.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 11, 2026 | $5.7M | — | -270.9% | −$13.9M | −$15.6M |
| Q1 2026 | 10-Q | May 12, 2026 | $4.6M | — | -309.5% | −$10.4M | −$21.7M |
| Q4 2025 | 10-K | Mar 10, 2026 | $5.6M | +41% | -307.6% | −$16.5M | $23.1M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $6.5M | +117% | -314.1% | −$19.7M | −$19.1M |
| Q4 2024 | 10-K | Mar 10, 2025 | $4.0M | — | -845.8% | −$28.7M | −$20.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Prelude Therapeutics
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A degraders and JAK2V617F mutant selective inhibitors -- new approaches to clinically validated targets with transformative potential for patients. We are leveraging our expertise in targeted protein degradation to create and develop next generation degrader antibody conjugates (DACs) with novel payloads. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.
In its own words, from its 8-K, filed Aug 11, 2026.
Prelude Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -270.9% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PRLD Prelude Therapeutics | Q2 2026 | $5.7M | — | -270.9% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Prelude Therapeutics 10-Q on SEC EDGAR · CIK 1678660 · Pharmaceutical Preparations
13F: who owns PRLD and who is buying
More on PRLD
- How Prelude Therapeutics makes money: revenue by segment
- Prelude Therapeutics next earnings date and what analysts expect
- Prelude Therapeutics stock forecast, price target and fair value
- Who owns Prelude Therapeutics stock: holders, funds and Congress trades
- Prelude Therapeutics recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q4 2024 results